Medical Health & Life Science Research News

New report shares details about the cystic fibrosis therapeutics market

Medical Market Research

The market for Cystic Fibrosis Therapeutics is anticipated to grow with double digit CAGR during the forecasting period. Cystic fibrosis is among the most common life-threatening genetic disorders worldwide.

Complete report available at www.marketreportsonline.com/680598.html.

It is caused by defects in a single gene known as the cystic fibrosis transmembrane conductance regulator, or CFTR.

The increasing prevalence of cystic fibrosis, rising awareness about cystic fibrosis therapy, strong pipeline candidates, technological advancement and high rate of R&D initiatives are some of the major factors that are driving cystic fibrosis therapeutics market. However, high cost involved in treatment, increase in complexity of disease are restraining the cystic fibrosis therapeutics market.

Key Highlights of the Cystic Fibrosis Therapeutics Market Report:

United States dominates the global market for cystic fibrosis therapeutics.

The EU5 countries together accounted for over 20% share of the global cystic fibrosis market in 2016.

In Asian region, the prevalence of Cystic Fibrosis is observed to be very low in countries like China, India and Japan.

On the basis of pharmacological class, the CFTR modulator captures highest share of the total CF therapeutics market in 2016.

Report at www.marketreportsonline.com/contacts/name=680598.

In 2016, mucolyctics agents accounted for around xx% of the global cystic fibrosis therapeutics market.

Cystic Fibrosis patients who have reduced the levels of digestive enzymes due to improper functioning of pancreas, are treated by PERT to replace these enzymes.

In 20XX, TOBI Podhaler generated sales worth US$ 300 Million.

Italy has followed Ireland and other EU countries such as Germany, Austria, Denmark and Luxembourg in approving Orkambi for patients with CF.

It's estimated that 1 in every 2,500 babies born in the UK has cystic fibrosis.

The revenues for Creon increased 22 percent in 2015, driven primarily by continued market growth.

Zenpep sales surpassed US$ 200 Million mark in 2016.

Some of the drugs that are under clinical studies are Tezacaftor (VX-661) + ivacaftor, VX-445 + tezacaftor + ivacaftor, VX-659 + tezacaftor + ivacaftor, PTI-428, AZD5634, QR-010 and POL6014 among many others.

The report titled “Cystic Fibrosis Therapeutics Market (By Major Marketed Products, Pharmacological Class, & Geography) and Pipeline Analysis – Global Forecast to 2024” provides a comprehensive assessment of the Cystic Fibrosis Therapeutics Market.

 

News From

MarketReportsOnline - Industry Research Analysis StoreMarketReportsOnline
Category: Market Research Publishers and RetailersCompany about: MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.
This email address is being protected from spambots. You need JavaScript enabled to view it.